Gland Pharma Q2 FY27 Results Awaited After ₹1,800 Crore Q1

Gland Pharma Limited’s Q2 FY27 figures remained unverified on November 6, 2026, after it reported ₹1,800.27 crore in Q1 FY27 sales, up 19.57% year on year, and net profit of ₹316.96 crore. The board was scheduled to consider the July-September quarter results on Friday, making the release important for assessing whether recent growth continued.

When will Gland Pharma report Q2 FY27 results?

Gland Pharma was scheduled to announce its unaudited Q2 and H1 FY27 financial results on November 6, 2026, for the quarter and half year ended September 30, 2026. However, the available information states that the Q2 FY27 statement had not yet been published or verified at the time of the update.

The company had earlier informed exchanges about an earnings conference call at 6:30 pm IST on November 6. Management is expected to discuss the quarter’s performance and business updates during the call. The company said the call transcript and recording would be made available on its website afterward.

Ahead of the results, Gland Pharma closed its trading window from October 1 under the Securities and Exchange Board of India’s insider-trading regulations. The window is set to reopen 48 hours after the declaration of the unaudited Q2 and H1 FY27 results.

What did Gland Pharma report in Q1 FY27?

Gland Pharma reported Q1 FY27 net sales of ₹1,800.27 crore, compared with ₹1,505.62 crore in Q1 FY26 and ₹1,742.79 crore in Q4 FY26. This represented year-on-year growth of 19.57% and sequential growth of 3.30%.

Net profit for the June 2026 quarter was ₹316.96 crore, up from ₹215.48 crore a year earlier. The company’s profit was nevertheless lower than ₹366.68 crore reported in the March 2026 quarter, a sequential decline of 13.56%.

The latest quarterly figures showed total income of ₹1,861.50 crore, including other income of ₹61.23 crore. EBITDA stood at ₹550.60 crore, while operating profit was ₹489.37 crore. These numbers provide the base against which investors will compare the September-quarter release once filed.

What will investors monitor in the September quarter?

Investors will monitor whether sales growth, profitability and management’s FY27 outlook remain consistent with the June-quarter performance. The available data does not provide Q2 FY27 financial figures, so any assessment of growth, margins or earnings trends must wait for the formal filing.

A key point will be the company’s constant-currency revenue-growth guidance. One management reference indicated FY27 revenue growth guidance of 15% on a constant-currency basis, with scope to exceed that level if a constrained vial line received US Food and Drug Administration approval. Another reference to a May 2026 call cited consolidated growth guidance of 12-13% on a constant-currency basis.

The difference between the two cited guidance levels makes management commentary relevant. The formal results and earnings call may clarify the applicable outlook, the operational position of the vial line, and the factors affecting the company’s sales trajectory.

Why do Gland Pharma’s Q2 results matter to the market?

Gland Pharma’s September-quarter report matters because its Q1 results showed strong year-on-year expansion but a lower profit than the immediately preceding quarter. Sales rose nearly 20% year on year in Q1 FY27, while net profit increased more than 47%, indicating a materially stronger result than the June 2025 quarter.

At the same time, Q1 EBITDA of ₹550.60 crore was below the ₹624.49 crore recorded in Q4 FY26, and net profit was also lower sequentially. The Q2 filing will therefore help investors distinguish between quarterly variation and a broader operating trend.

Over the 20 quarters cited in the available data, quarterly sales increased from ₹1,080.47 crore in Q2 FY22 to ₹1,800.27 crore in Q1 FY27. Net profit moved from ₹302.08 crore to ₹316.96 crore over the same period. This longer record shows revenue expansion, while also highlighting that quarterly profitability can vary significantly.

Conclusion

Gland Pharma enters its Q2 FY27 reporting date after recording ₹1,800.27 crore in Q1 sales and ₹316.96 crore in net profit. The September-quarter figures were not verified in the available record, so the June-quarter results remain the latest confirmed financial reference point.

The next items to watch are the formal Q2 and H1 FY27 filing, management’s explanation of constant-currency growth guidance, and updates on the constrained vial line’s FDA approval status. The November 6 earnings call is scheduled to provide management commentary after the results process.